Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE versus MOBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE versus MOBAN.
LOXITANE vs MOBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the mesolimbic pathway. It also has affinity for serotonin 5-HT2A, histamine H1, alpha1-adrenergic, and muscarinic receptors.
MOBAN (molindone) is an antipsychotic agent with mechanism of action not fully defined, but believed to involve dopamine D2 receptor blockade in the mesolimbic system, with minimal extrapyramidal effects due to weak D2 binding and possible serotonergic modulation.
Oral: Initial 10 mg twice daily; may increase up to 250 mg/day in divided doses. IM: 12.5-50 mg every 4-6 hours.
Oral: 50-100 mg/day in 3-4 divided doses, increase to 225 mg/day for severe conditions; maximum 400 mg/day. IM: 50-100 mg every 4-6 hours; maximum 400 mg/day.
None Documented
None Documented
12-18 hours (terminal). Steady state achieved within 3-5 days; dosing adjustments for renal/hepatic impairment.
Terminal elimination half-life: 6-8 hours for parent drug; active metabolite (molindone) half-life ~12-15 hours; steady-state reached in 2-3 days.
Renal excretion accounts for 50-60% (primarily as metabolites, <1% unchanged). Fecal/biliary elimination accounts for 25-35% (via bile).
Renal: 70-80% as metabolites and unchanged drug; biliary/fecal: ~20%.
Category C
Category C
Antipsychotic
Antipsychotic